Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels
- 1 March 2016
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 44 (3) , 172-176.e1
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
This publication has 9 references indexed in Scilit:
- The stability of epigenetic factor ASXL1 is regulated through ubiquitination and USP7-mediated deubiquitinationLeukemia, 2015
- Loss of Asxl1 leads to myelodysplastic syndrome–like disease in miceBlood, 2014
- Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndromeBlood Cancer Journal, 2014
- Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivoJournal of Experimental Medicine, 2013
- Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsJournal of Clinical Investigation, 2013
- ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene RepressionCancer Cell, 2012
- Genetic Reevaluation of the Role of F-Box Proteins in Cyclin D1 DegradationMolecular and Cellular Biology, 2012
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryBlood, 2011
- Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2011